Bio Medica Laboratories PE ratio history and valuation
NSE: BMLLPharmaceuticals & Biotechnology
Bio Medica Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2026 · Issue price ₹139
Last close ₹149.95up ₹3.85 (2.64%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹146.10.
30 Oct: open ₹148.00, high ₹150.00, low ₹148.00
Range of traded prices from listing on 29 May 2026 to 30 Oct 2026
₹101.50Low, 3 Jun 2026₹181.00High, 4 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹189 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.16
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in May 2026
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 44.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 1.97
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,000100.0% delivered
Bio Medica Laboratories' P/E, price to sales, dividend yield and earnings yield on 30 Oct 2026. Each gets a history once a year of trading is on record. The P/E is the market cap over the profit of the twelve months to Mar 2026.
Bio Medica Laboratories PE ratio and valuation against its own history
- Price to earnings16.16today
- Price to bookThe share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.4.92today
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.A period of the last twelve months does not state its operating profit
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.6.19%today
Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to earnings =Market cap÷Net profit, last twelve monthsNet profit, last twelve months. Net profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹12 Cr
- Price to book =Market cap÷Net worth, consolidatedNet worth, consolidated. Shareholders' equity of the company and its subsidiaries together, in the consolidated balance sheet at Mar 2026.₹27 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹38 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹23 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹0.03 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.1,25,75,001at 30 Sep 2026
- Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary
- ₹26 Cr
Standalone accounts, the twelve months to Mar 2026, ₹ crore.Bio Medica Laboratories financials ›
Bio Medica Laboratories market cap, since Jun 2026
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Earnings per share
From the close on 30 Oct 2026, with the last twelve months' results.
- Earnings per shareEarnings per share, trailing. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) divided by the number of shares in issue.
- ₹9.28
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹61 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Bio Medica Laboratories is 129th among them by market cap. Each median leaves out Bio Medica Laboratories itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 27.8Across 157 other companies
- Listed companies with this P/E or lowerP/E among all listed companies. The share of the 3,409 listed companies with a trailing P/E on 30 Oct 2026 whose P/E is at or below Bio Medica Laboratories'.
- 40%Of 3,409 companies with a P/E
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 191 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.1Across 145 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.49%Across 90 other companies
| Company | |||||
|---|---|---|---|---|---|
 Nectar LifesciencesNECLIFE | 198 | – | 0.34 | – | 0.00% |
 Achyut HealthcareACHYUT | 197 | – | 5.59 | 819.4 | 0.00% |
 Gennex LaboratoriesGENNEX | 195 | 10.60 | 0.88 | 8.3 | 0.00% |
 Kerala AyurvedaKERALAYUR | 192 | – | – | – | 0.00% |
| Bio Medica LaboratoriesBMLL | 189 | 16.16 | – | – | 0.00% |
 Syschem (India)SYSCHEM | 180 | – | 1.29 | 8.7 | 0.00% |
 Brooks LaboratoriesBROOKS | 178 | 13.50 | 1.45 | 30.7 | 0.00% |
 Oxygenta PharmaceuticalOXYGENTAPH | 175 | – | – | – | 0.00% |
 Coral LaboratoriesCORALAB | 173 | 9.01 | 0.83 | 5.7 | 0.41% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.